How is Dupilumab Revolutionising COPD Care?  

Chronic obstructive pulmonary disease or COPD is the third leading cause of death worldwide, killing over 3 million people, predominantly in low and middle-income countries. It remains the seventh leading cause of poor health worldwide.
The most common cause of COPD is tobacco smoking. Other risk factors include indoor and outdoor air pollution including the burning of coal and wood, exposure to dust and occupational irritants and genetics, such as alpha-1 antitrypsin deficiency.
Treatment is complicated and relies on Bronchodilators, Anti-inflammatories, antibiotics, anticholinergics and leukotriene modifiers. A new paper published in the New England Journal of Medicine looked at the use of monoclonal antibodies in patients with Type 2 inflammation.
Read here: www.nejm.org/d....
Join this episode with Prof. Klaus Rabe, Professor of Pulmonary Medicine at the University of
Kiel and Director of LungClinic in Grosshansdorf.
Interview with Prof. Klaus Rabe:
1:49 Paper published in the New England Journal of Medicine
2:21 Summarise the key findings of the new paper published in the New England Journal of Medicine
5:59 How does this data on Dupilumab revolutionise care in COPD?
--------------------------------------------------------------------------------------------------------------------------
📽 Subscribe to our RU-vid Channel for our latest videos on Allergies and Airway Diseases
bit.ly/3eMvc3E
--------------------------------------------------------------------------------------------------------------------------
📧 Get in touch with the EUFOREA team for any questions
bit.ly/2OtlIQp
--------------------------------------------------------------------------------------------------------------------------
📌 EUFOREA is an international non-profit organisation aiming to implement optimal patient care for allergies and airway diseases (asthma, chronic rhinosinusitis, rhinitis) and comorbidities through education, research and advocacy. #euforea
📍Follow us on social media
Twitter: bit.ly/38wrrM7
LinkedIn: bit.ly/2OqtWsf
Instagram: bit.ly/3TGB5jM
​Facebook: bit.ly/3cnNyFF